Advancing real-time monitoring of AAV vector processes

Cell & Gene Therapy Insights 2021; 7(9), 1183–1194


Published: 11 October 2021
Rachel Legmann, Joe Ferraiolo


Rachel Legmann

Director of Technology, Gene Therapy

Rachel has more than 25 years of experience in the field of scalable biologics and gene therapy manufacturing of therapeutic products, viral vectors and proteins for gene therapy and biologics. She completed her Ph.D. in Food Engineering and Bio-technology at the Technion-Israel Institute of Technology, Israel. Rachel joined Repligen in 2021 as a subject matter expert leading the global gene therapy organiza-tion helping customers achieve their technical and operational objectives in their manufacturing of vector-based therapeutics and vaccines with a focus on gene therapy processes including upstream, downstream, analytics and scalability. In addi-tion to supporting global customers and building high level networks, Rachel is sup-porting various internal cross-functional activities and external collaborations. Prior to joining Repligen, Rachel held several scientific and leadership roles at Microbiology and Molecular Genetics department at Harvard Medical School, CRO SBH Sciences, Sea-horse Biosciences part of Agilent, CDMO Goodwin Biotechnology and Pall Corp part of Danaher.


Joe Ferraiolo

Associate Director Bioanalytics, Repligen

Joe is the Associate Director Bioanalytics for Repligen. He is in charge of the Bioana-lytics Applications department related to the SoloVPE Variable Pathlength UV solu-tion. He has been with the company for more than 20 years, with over 10 years of development and validation experience in analytical applications. He specializes in UV analysis and leads the development and commercialization of high-value products and flexible solutions that address critical steps in the production of biologic drugs, gene therapy solutions, and monoclonal antibodies.

Listen to the full podcast:

Listen to each individual question and answer: